Envisagenics

Summary

This business focuses on the development of RNA therapeutics using advanced technologies such as Artificial Intelligence and Machine Learning. Their proprietary SpliceCore® software platform enhances the discovery of drug targets by analyzing RNA sequencing data, allowing for faster and more precise identification of therapeutic targets. The platform is particularly adept at detecting splicing variations, which are critical for developing effective RNA-based therapies. Additionally, they have a specialized branch, SpliceIO™, that targets tumor-specific neoepitopes for immunotherapy applications.